1. Assessing Adherence to Cardiac Monitoring Guidelines in Trastuzumab-Treated Breast Cancer Patients: Insights From a Tertiary Hospital
   Abeer Alhuthali et al, 2023, Cureus CrossRef
2. GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy
   Chunyu Tian et al, 2024, Frontiers in Pharmacology CrossRef